Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Vigonvita Life Sciences Co's Net Margin % or its related term are showing as below:
HKSE:02630'
s Net Margin % Range Over the Past 10 Years
Min: -1786.67 Med: -348.42 Max: 6.06
Current: -348.42
HKSE:02630's Net Margin % is ranked worse than 94.48% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.54
vs HKSE:02630: -348.42
Vigonvita Life Sciences Co (HKSE:02630) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vigonvita Life Sciences Co Net Margin % Related Terms
Vigonvita Life Sciences Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co Net Margin % Chart
Vigonvita Life Sciences Co Annual Data
Trend
Dec23
Dec24
Dec25
Net Margin %
6.06
-1,786.67
-348.42
Vigonvita Life Sciences Co Semi-Annual Data
Dec23
Dec24
Dec25
Net Margin %
6.06
-1,786.67
-348.42
HKSE:02630 vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vigonvita Life Sciences Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vigonvita Life Sciences Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co (HKSE:02630) has a Net Margin % of -348.42% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vigonvita Life Sciences Co and its competitors. According to the industry distribution chart, Vigonvita Life Sciences Co ranks #908 out of 961 companies in the Drug Manufacturers industry, placing it in the top 94.5%.
Is Vigonvita Life Sciences Co's Net Margin % too high?
Vigonvita Life Sciences Co's current Net Margin % is -348.42%. Based on the distribution chart, Vigonvita Life Sciences Co ranks #908 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Vigonvita Life Sciences Co ranks #908 out of 961 companies for Net Margin %. This places Vigonvita Life Sciences Co in the lower half of its industry. The industry median Net Margin % is 5.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.54, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vigonvita Life Sciences Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vigonvita Life Sciences Co's current Net Margin % is -348.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Net Margin % of -348.42%. The current Net Margin % is -348.42%. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Net Margin % is -348.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score
Get the complete analysis for HKSE:02630
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02630 has been successfully added to your 
